Oncology · Small MoleculeRegulatory Approvalregulatorymid-term

FDA Accepts Supplemental NDA for Romvimza (Vimselitinib) by Deciphera Pharmaceuticals

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Deciphera Pharmaceuticals3 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 6:30:31 PM

Assessment confidence: 57% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental NDA for Romvimza positions Deciphera Pharmaceuticals favorably within the oncology sector. This development necessitates close monitoring of the FDA review timeline and potential competitive responses from other oncology therapies. Regulatory context from FDA (FDA AP — ROMVIMZA (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market impact and prepare for competitive responses from other oncology therapies. The strongest clinical anchor is A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) (ClinicalTrials.gov), sponsor/company relevance (merck). In Oncology · Small Molecule, 3 regulatory and 4 competitive items passed relevance filtering for Deciphera Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer. This acceptance may enhance Deciphera's position in the oncology market, particularly in the treatment of specific cancers targeted by vimselitinib.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ROMVIMZA (SUPPL) (FDA). Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The acceptance of the supplemental NDA indicates a step forward in the regulatory process, but the final approval will depend on the outcomes of the FDA's review.

Key Risks

Elevated medium regulatory exposure for Deciphera Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful approval could enhance Deciphera's market share and revenue potential in oncology, particularly for specific cancer treatments targeted by vimselitinib.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Oncology · PD-1 Inhibitor · Regulatory Approval · This acceptance may enhance Merck's competitive positioning in the oncology market, particularly in combination therapies.
Upside for Deciphera Pharmaceuticals may improve if Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA review process and any upcoming data releases related to vimselitinib's efficacy and safety.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ROMVIMZA (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Suction Mini-PCNL Versus Standard PCNL for the Management of 2-4cm Kidney Stones
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Small RNA tRF-31 Changes in Patients With Age-Related Cataract
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts Supplemental Application for KEYTRUDA QLEX
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-depende
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Genetic variants of the transporter SLC22A4 affect the abundance and survival of Fusobacterium nucleatum in colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Targeted proteoform degradation for precision drug design, delivery, and therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Deciphera Pharmaceuticals
Romvimza (vimselitinib)

Commercial impact

medium

Successful approval could enhance Deciphera's market share and revenue potential in oncology, particularly for specific cancer treatments targeted by vimselitinib.

Regulatory impact

medium

The acceptance of the supplemental NDA indicates a step forward in the regulatory process, but the final approval will depend on the outcomes of the FDA's review.

What to watch

Monitor the timeline for the FDA review process and any upcoming data releases related to vimselitinib's efficacy and safety.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.